C-FDAPOlatec
NLRP3 antagonists, inflammasome inhibition, oral therapeutics
modulatingsmall molecule
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-FDAP
C-FDAPC-FDAPNLRP3 antagonists, inflammasome inhibition, oral therapeutics
0-100 chain-logic scale · 15 dimensions · scored on public evidence
The purpose of this trial is to investigate the efficacy and safety of dapansutrile (OLT1177®) tablets in subjects with an acute gout flare.
The purpose of this study is to assess the safety and efficacy of orally administered NLRP3 inhibitor, dapansutrile, for the treatment of moderate COVID-19 symptoms and early cytokine release syndrome (CRS) in patients with confirmed SARS-CoV-2 infection and moderate symptoms. Coronavirus disease 2019 (COVID-19) is caused by infection from a new strain of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). COVID-19 is characterized by fever, cough and shortness of breath, which in certain patients can lead to systemic organ failure and mortality. The data show that SARS-CoV-2 activates the innate immune signaling sensor NLRP3. Activation of NLRP3 initiates the cytokine release syndrome (CRS), which includes the production of primary cytokine, IL-1, triggering an intense inflammatory response that is prevalent in symptomatic COVID-19 patients. When CRS advances further to a fulminant 'cytokine storm', the data show that respiratory distress syndrome and multiple-organ failure take place. A specific inhibitor of NLRP3, dapansutrile may reduce or prevent the hyperinflammation associated with CRS by inhibiting the production of IL-1β early to arrest the progression to a severe 'cytokine storm.' The end result would be a reduction in the need for COVID-19 patients to receive intensive medical treatment, allowing for fewer hospitalizations, administration of mechanical ventilation and deaths.
This is a Phase 1b randomized, double-blinded, single-center safety and pharmacodynamics study of sequential cohort, dose-escalating, repeat-dosing of dapansutrile or placebo (4:1 ratio) in subjects with stable systolic heart failure (HF) with LVEF≤40% symptomatic for NYHA functional classification II-III who show signs of systemic inflammation (high sensitivity plasma C reactive protein \[hsCRP\] \> 2 mg/L). A total of 30 subjects will be enrolled in 3 sequential cohorts by randomized allocation (8 active and 2 placebo within each cohort). Progression to cohort 2 with dose escalation will occur following the Day 28 visit of the last subject in the first cohort. Progression to cohort 3 with dose escalation will occur following the Day 8 visit of the last subject in the second cohort. Subjects will be screened and evaluated twice for eligibility: 1) at the time of Screening (up to 28 days prior to enrollment); and 2) at the Baseline visit, prior to randomization. Following enrollment, Baseline assessments will be conducted and the first dose of investigational product (either dapansutrile capsules or placebo capsules) will be administered at the clinical site upon completion of all assessment and collection of baseline parameters. Subjects will then self-administer investigational product once, twice or four times daily, depending on cohort, for up to fourteen (14) consecutive days beginning at the Baseline visit and continuing through the planned Day 14 visit. Subjects will return to the study clinic on Days 4, 8, 14 and 28 for follow-up visits. Additionally, subjects will be contacted for telephone follow-up on Day 42.
This is a pilot, open-label Phase 2, single-center, repeat dose, single cohort, proof-of-concept, safety, pharmacodynamics and efficacy study of dapansutrile capsules to be conducted in subjects with Schnitzler's syndrome (SchS) currently well controlled by anakinra therapy. At least 5 but no more than 10 subjects will be enrolled.
This study is a randomized, placebo-controlled, sequential ascending-dose study of healthy volunteers after administration of single or multiple dose(s) of investigational drug (OLT1177 Caps or Placebo Caps). A total of 36 subjects will be enrolled across 6 cohorts, and subjects in each cohort will be randomized in a ratio of 5 active to 1 placebo.
The objectives of this trial are to investigate the efficacy and safety of six weeks of treatment with OLT1177 Gel in subjects with moderate to severe pain associated with osteoarthritis of the knee following cessation of pain therapy.
The purpose of this trial is to investigate the efficacy and safety of OLT1177 Gel in subjects with moderate to severe pain associated with osteoarthritis of the knee following cessation of pain therapy.
The purpose of this study is to determine if OLT1177 Gel is safe and can be tolerated when given as a single dose and multidose to a defined area of one knee of healthy subjects.
Craig T. Basson, MD, PhD Joins Olatec Therapeutics’ Board of Directors - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Business Craig T. Basson, MD, PhD Joins Olatec Therapeutics’ Board of Directors August 16, 2022 | 6 min read Twitter LinkedIn Facebook Email Print Olatec Therapeutics LLC, a leader in the developing class of selective NLRP3 inhibitors, today announced that Craig T. Basson, MD, PhD has been elected to … Scholar. Dr. Basson holds an MD and PhD from Yale University. He completed his residency in Internal Medicine at Johns Hopkins Hospital and his clinical Cardiology fellowship and postdoctoral Cardiovascular Genetics fellowship at Harvard University and the Brigham and Women’s Hospital. Dr. Basson is an elected member of the American Society for Clinical Investigation and a Fellow of the American Heart Association and of the American College of Cardiology. Currently, Dr. Bass … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Olatec Therapeutics Announces Results Showing Dapansutrile Reduces Tumor Growth in a Mouse Model of Melanoma - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Pharm Country Olatec Therapeutics Announces Results Showing Dapansutrile Reduces Tumor Growth in a Mouse Model of Melanoma April 28, 2021 | 6 min read Twitter LinkedIn Facebook Email Print Olatec Therapeutics LLC (Olatec) today announced the first publication from its preclinical studies with dapansutrile in selected ca … bsp; 2 min read · Tristan Manalac Podcast AbbVie keeps M&A rolling, FDA’s reversal train chugs along, BIO 2026 dispatch, more June 24, 2026 · 1 min read · Jef Akst China BIO 2026: US needs to dodge China’s ‘inescapable dependencies’ to protect biotech June 24, 2026 · 2 min read · Annalee Armstrong BioSpace at BIO to find out" href="https://www.biospace.com/drug-development/can-adcs-be-kin … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Olatec Therapeutics Announces Publication of Preclinical Research on Oral NLRP3-Specific Inhibitor Dapansutrile in Pancreatic Ductal Adenocarcinoma - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA M … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Pharm Country Olatec Therapeutics Announces Publication of Preclinical Research on Oral NLRP3-Specific Inhibitor Dapansutrile in Pancreatic Ductal Adenocarcinoma October 3, 2023 | 9 min read Twitter LinkedIn Facebook Email Print Olatec Therapeutics LLC (Olatec) today announced a publication in Cancer Research Communicat … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
%PDF-1.3 %��������� 6 0 obj > stream x�\[sݶ~篠d˦."^�8�q��%��}���i:�w&������ ��77����ʿ����)�G��x�8ܟ�x�$�?=-]Y}���4\�¿���E���N8�����)����yS����%K Y���i IQL��0�Ϳ�蚾7���M2(|�o߸�`�9m(�D�E}E�F�\f�ý �Ʒ0)2Ws|1�R4O�������V(�B��9���&� �~�����6QW !�*�� �)�N0���C_b��' S��ېup!6�o�y�9"צ6!�����?�y|Z�'��j�� ! �Ǩ��-V ��{�c������Bf��P�h����k�B�F�,��S��a2�� ��TGg�c�0ф� � �ߥ _A�x,w�v�nM�W���;Y�؆@�SD���z����OSX�R��%q]kM�`�8W�U�h9t Y�j����ҡ��] �O�T,�VL0a{h�Q7�;d�4�����o������. ȵǁ�� (� �q%\�B� F=���� X�G����±�)U-��b(�MQ��3,p���7(��ה��q>~g,+����P�!�� �ph&_SH�P��:*���1"S�Eݮ
First Patient Enrolled in a Phase 2 Study in Patients with Type 2 Diabetes with Olatec's NLRP3 Inhibitor, Dapansutrile Accessibility Statement Skip Navigation Resources Investor Relations Journalists Agencies Client Login Send a Release News Products Contact Search Search When typing in this field, a list of search results will appear and be automatically updated as you type. Searching for your content... No results found. Please change your search terms and try again. News in Focus Browse News Releases All News Releases All Public Company English-only News Releases Overview Multimedia Gallery … tform Login ProfNet Data Privacy Do not sell or share my personal information : Submit via [email protected] Call Privacy toll-free: 877-297-8921 Contact PR Newswire Products About My Services All News Releases Platform Login ProfNet Call PR Newswire at 888-776-0942 Terms of Use Privacy Policy Information Security Policy Site Map RSS Cookies Copyright © 2026 Cision US Inc. --> -->
April 27, 2026 - DEF 14A: Definitive proxy statements | Definium Therapeutics (DFTX) April 27, 2026 > Form DEF 14A > Definium Therapeutics Document Links Form: DEF 14A Definitive proxy statements April 27, 2026 DEF 14A: Definitive proxy statements Published on April 27, 2026 0001813814 false DEF 14A 0001813814 2025-01-01 2025-12-31 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by th … ment, if other than the Registrant) Payment of Filing Fee (Check all boxes that apply): ☒ No fee required. ☐ Fee paid previously with preliminary materials. ☐ Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11. Table of Contents DEFINIUM THERAPEUTICS, INC. One World Trade Center, Suite 8500 New York, New York 10007 (212) 220-6633 NOTICE OF ANNUAL GENERAL AND SPECIAL MEETING OF SHAREHOLDERS To be held on June 11, 2026 at 10:00 a … m/DFTX2026 on June 11, 2026 at 10:00 a.m. Eastern Time. To participate, vote or submit questions during the Annual Meeting, shareholders or their proxyholders must log on to the virtual meeting platform by entering the 16-digit control number included on your proxy card, Notice of Internet Availability of Proxy Materials (“ Notice ”) or voting instruction form. Online access to the Annual Meeting will open approximately 15 minutes prior to the start of the virtual meeting. Th … oard ”) to hold office until the 2027 annual general meeting of shareholders (“ Proposal No. 1 ”); (2) To appoint KPMG LLP (“ KPMG ”) as independent registered public accounting firm (auditor) for the Company until the 2027 annual general meeting of shareholders (“ Proposal No. 2 ”); (3) To consider and, if deemed advisable, approve the amendment to the Definium Therapeutics, Inc. 2025 Equity Incentive Plan (the “ 2025 Equity Incentive Plan ”) to increase the number of common … of common shares available for issuance under the 2025 Equity Incentive Plan (“ Proposal No. 3 ”) by 5,000,000 common shares; and (4) To conduct any other business properly brought before the Annual Meeting and any adjournment or postponement thereof. These items of business are more fully described in the proxy statement accompanying this Notice
DevelopmentAid For full functionality of this site it is necessary to enable JavaScript. Here are the instructions how to enable JavaScript in your web browser .
Olatec - 2026 Company Profile, Team, Funding & Competitors - Tracxn JavaScript is disabled in your browser. enable it to enjoy the full features of Tracxn. Your browser was unable to load all of Tracxn resources. They may have been blocked by your firewall, proxy or browser configuration. Press Ctrl+F5 or Ctrl+Shift+R to have your browser try again and if that doesn't work, click here to retry or mail us at [email protected] Internal Server Error Toggle navigation Customers Investment Industry Venture Capital Funds Private Equity Funds Accelerators & Incubators Investment Banks Corpor … nited States Stage Series A Total Funding $40M in 2 rounds Latest Funding Round Grant (prize money), Mar 10, 2023 , $***** Investors Sanders Morris Harris Group & 3 more Ranked 42 nd among 296 active competitors Employee Count 14 as on Mar 31, 2026 Similar Companies Philogen & 357 more View Olatec's full profile Sign up to download Olatec's company profile Sign Up for Free Olatec's funding and investors Olatec has raised a total funding of $40M over 2 r … . Its first funding round was on Feb 23, 2023 . Its latest funding round was a Grant (prize money) round on Mar 10, 2023 for $ ***** . 1 investor participated in its latest round. Olatec has 4 institutional investor s . Here is the list of recent funding rounds of Olatec : Date of Funding Funding Amount Round Name Post-Money Valuation Revenue Multiple Lead Investors Other Investors Mar 10, 2023 8201626 Grant (prize money) 6793225 2903357 8510289 5301253 Feb 23, 2023 7310112 … Institute Business Wire • May 16, 2023 • Olatec • Olatec Therapeutics Awarded a Grant from The Michael J. Fox Foundation in Collaboration With Medical University of Innsbruck to Evaluate Dapansutrile ACROFAN • Mar 10, 2023 • Olatec , The Michael J. Fox Foundation • Olatec Therapeutics Announces the Final Closing, Led by Sanders Morris Harris, on Its $40 Million Series A Financing Round Business Wire • Feb 24, 2023 • Olatec , Sanders Morris Harris Group , Advection Growth Capi … the latest funding round of Olatec? Olatec's latest funding was a $ ***** Grant (prize money) round on Mar 10, 2023 , with participation from 1 investor . Who are the top competitors of Olatec? Olatec's top competitors include Philogen , Escient Pharmaceuticals and Septerna . Among them, Evommune secured the most recent funding round i
NMRA-215 - Drug Targets, Indications, Patents - Synapse Products Data Feature Plans Request Demo Sign Up for Free Last update 30 May 2026 NMRA-215 Last update 30 May 2026 Overview R&D Status Clinical Result Translational Medicine Deal Core Patent Clinical Trial Approval Regulation Overview Basic Info Drug Type Small molecule drug Synonyms NMRA 215, NMRA215 Target NLRP3 Action inhibitors Mechanism NLRP3 inhibitors(NACHT, LRR and PYD domains-containing protein 3 inhibitors) Therapeutic Areas Nervous System Diseases Endocrinology and Metabolic Disease Active Indication Obesity Parkinson Disea … ects that its cash and cash equivalents as of March 31, 2026, will enable it to fund its operating plan into the third quarter of 2027. R&D Expense: Research and development expenses for the first quarter of 2026 were $38.6 million, as compared to $52.2 million for the same period in 2025. The decrease was primarily due to a reduction in clinical trial costs, and lower personnel-related costs. G&A Expense: General and administrative expenses for the first quarter of 2026 were … rights; and other matters that could affect sufficiency of capital resources to fund operations. For a detailed discussion of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Neumora’s business in general, please refer to the risk factors identified in the Company’s filings with the Securities and Exchange Commission (SEC), including but not limited to its Quarterly Rep … stitute for Regenerative Medicine: CIRM awarded over $111 million in its latest grant announcement . That included grants for $8 million or $15 million to fund clinical studies from Mahzi Therapeutics, Cellio Therapeutics and Immusoft. Mahzi is developing a gene therapy for a rare condition called Pitt-Hopkins syndrome, while Cellio is developing a stem cell-derived therapy to restore vision. Immusoft is developing an engineered B cell therapy for the rare lysosomal storage d
Craig Basson Joins Olatec Therapeutics’ Board of Directors | FirstWord PHARMA You need to enable JavaScript to run this app. Loading...
%PDF-1.7 %���� 1 0 obj >/Lang(pl)/Metadata 6995 0 R >> endobj 3 0 obj >/ExtGState >/ProcSet[/PDF/Text/ImageB/ImageC/ImageI]/Font >>>/MediaBox[ 0 0 960 540]/Contents 4 0 R /Parent 2 0 R /Type/Page/Tabs/S/Group >>> endobj 4 0 obj >stream x��[]�]�q}��p �:��`�,;H�u��E � � 9�j$�3k͐�WN�ց�!79$����ܗ���� �������>����'��!��R���p�������ǧO^��z�῟>�� V��b��R��� V ���� �-�{*���m�R��vtﹶ~ ��*�^�t�c��vi�����۟�k�7�}}(� j|z��>���7c�}����E��>'�H���h������ݏ��>{���s /��ݏ?ܞ���ſ|��ի��7� �%�*��X�������q����:��-�� ��n�>¸}�^[�Iڸ��3#E���^�F��Q�?����L�~��E�,��3���W/��.=���WU~�/^��XR����WUj�����U�H #�R��
Olatec Presents Preclinical Evidence of Dapansutrile Activity in Parkinson's Menu Advanced Structure search List search Wish Lists Cart Sign in Sign in For suppliers --> Contact us Catalog of Screening Compounds Screening Libraries Building Blocks Al/ML Data sets new 1B virtual space new Advanced Structure search List search Homepage > Company > Media > Pharma News > 2026 > Olatec Presents Preclinical Evidence of Dapansutrile Activity in Parkinson's Olatec Presents Preclinical Evidence of Dapansutrile Activity in Parkinson's Olatec Presents Preclinical Evidence of Dapansutrile Activity in P
XBRL Viewer Please enable JavaScript to use the EDGAR Inline XBRL Viewer.
Clinical Stage Partnering Terms and Agreements in Pharmaceuticals and Biotechnology 2020-2026 Your browser is not supported. To avoid security issues and to comply with web standards, please upgrade to a modern browser. ABOUT US CONTACT US FAQ  USD EUR GBP USD ▼ USD EUR GBP € EUR $ USD £ GBP +353-1-416-8900 REST OF WORLD +44-20-3973-8888 REST OF WORLD 1-917-300-0470 EAST COAST U.S 1-800-526-8630 U.S. (TOLL FREE)  Login / Register Contact Us About Us View Categories Our Services Our Services Back Market Research Custom Research Conferences … development partnerships. At the clinical stage, licensing agreements typically grant the licensee exclusive rights or options to develop a licensor’s product or technology, often covering Phase I, Phase II, and Phase III trials. These agreements are frequently multi-component, involving collaborative R&D, co-development, and commercialization strategies. This report provides detailed intelligence on the latest clinical-stage agreements in the healthcare sector, helping compa … as: What specific rights are granted in each agreement? What exclusivity terms apply? How is the deal structured financially? (Upfronts, milestones, royalties) Who controls development, manufacturing, and commercialization? How are intellectual property rights handled? What are the termination conditions for the agreement? What dispute resolution mechanisms are in place? How are confidentiality and publication rights managed? Gain the competitive edge - explore the report to … ustralian and New Zealand Children’s Haematology / Oncology Group Autism Impact Fund Autobahn Therapeutics Autonomous Therapeutics Avalo Therapeutics Avance Clinical Avania Avecho Biotechnology Avenue Therapeutics Avenzo Therapeutics AVEO Oncology Aveta Biomics AviadoBio Avid Bioservices AVM Biotechnology Awakn Life Sciences Axovant Gene Therapies Axovia Therapeutics Axsome Therapeutics Ayala Pharmaceuticals Azura Ophthalmics AzurRx BioPharma Bachem Baili Biopharmaceutical Ba … -Fite BioPharma Canadian Neuromuscular Disease Registry CanariaBio Cancer Focus Fund Cancer Prevention and Research Institute of Texas Cancer Research UK Candel Therapeutics Cantargia Cantex Pharmaceuticals Capricor Therapeutics CARB-X Cardiff Oncology Cardinal Health Care Access Research Caris Life Sciences Carisma Therapeutics Carrick Therapeut
Clinical Stage Partnering Terms and Agreements in Pharma --> Accessibility: Skip TopNav Clinical Stage Partnering Terms and Agreements in Pharma and Biotech: 1,775 Deals + SEC Contracts, Top 25 Dealmaker Profiles, 2020-2025 This data-driven resource analyzes 1,775 clinical-stage deals (Phase I–III) with headline values, upfronts, milestones, and royalty ranges, plus links to deal records and SEC-filed contracts where available. Content spans why companies partner, common structures (licensing, options, co-dev/commercialization), payment triggers, and trends by year, phase, therapy area, techno … development partnerships. At the clinical stage, licensing agreements typically grant the licensee exclusive rights or options to develop a licensor's product or technology, often covering Phase I, Phase II, and Phase III trials. These agreements are frequently multi-component, involving collaborative R&D, co-development, and commercialization strategies. This report provides detailed intelligence on the latest clinical-stage agreements in the healthcare sector, helping c … GLOBE NEWSWIRE) -- The "Optical Sorter Market by Offering, Type, Platform, Application - Global Forecast to 2032" has been added to ResearchAndMarkets.com's offering. The... Read More June 26, 2026 09:34 ET | Source: Research and Markets Furniture Plastic Industry Intelligence Report 2026-2030: Market Dynamics, Case Studies, Competitive Insights Dublin, June 26, 2026 (GLOBE NEWSWIRE) -- The "Furniture Plastic Market by Plastic Type, Composition, Furniture T … he "Furniture Plastic Market by Plastic Type, Composition, Furniture Type, Application, End-use Industry, and Region - Global Forecast to 2030" has been... Read More
10-K three years FY false 0001851194 0001851194 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-01-01 2021-12-31 0001851194 us-gaap:AssetBackedSecuritiesMember 2021-12-31 0001851194 us-gaap:CashEquivalentsMember us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001851194 vtyx:TwoThousandTwentyOneEmployeeStockPurchasePlanMember 2021-01-01 2021-12-31 0001851194 us-gaap:EmployeeStockOptionMember 2022-01-01 2022-12-31 0001851194 vtyx:TwoThousandAndTwentyTwoAtTheMarketSalesAgreementMember 2022-01-01 2022-12-31 0001851194 us-gaap:AccountingStandardsUpdate … eding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth comp … scovery and development approach and expertise to advance this pipeline, and to apply our knowledge of the immunology market to augment our pipeline through strategic partnerships.   Our Strategy   Our goal is to become a leader in developing differentiated product candidates for the immunology market and, ultimately, to address large, well-established commercial markets.   The three key elements to achieve this strategy include:   Focusing on the identifi … foreign patent applications. More specifically, we own one pending U.S. patent application, and more than twenty pending foreign patent applications with claims directed to our lead product candidate, VTX958, and other related compounds as a composition of matter, as well as claims directed to pharmaceutical compositions and uses of such compounds, including the use of VTX958, to treat inflammatory or autoimmune diseases, including psoriasis. Any patents that may issue from … h respect to our S1P1R program, we own one U.S. patent, one pending U.S. patent application, more than forty foreign patents (including in various European countries, Australia, China, Hong Kong, India, Israel, Japan, Macao, Mexico, and Russia), and eight pending foreign patent applications (in Brazil, Canada, China, Europe, Hong Kong, Japan, Kor
Dapansutrile Shows Promise in Parkinson's Disease Models | Olatec Therapeutics posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign
2014 Grand Marshal - Rumson St. Patrick's Day Parade Home About Meet The Board Charities and Gifts Our History About Rumson Past Grand Marshals > 2025 Grand Marshal 2024 Grand Marshal 2023 Grand Marshal 2022 Grand Marshal 2020 Grand Marshal 2019 Grand Marshal 2018 Grand Marshal 2017 Grand Marshal 2016 Grand Marshal 2015 Grand Marshal 2014 Grand Marshal 2013 Grand Marshal Blog Registration Parade Group Info SPONSORSHIPS Sponsorship Opportunities Program Journal Ads Friends Of The Parade Events MJL Irish Essay Competition Irish Heritage Poster Contest Irish Soda Bread Contest Erin Open > P … ards for public service is the National Institute of Social Sciences Gold Medal Award for Distinguished Service to Humanity, the BENS Eisenhower Award for Distinguished National Service, and The National Football Foundation and Hall of Fame Gold Medal Award. He was inducted into the College Football Hall of Fame in 1975, and West Point’s Army Sports Hall of fame in 2005. Pete was selected in the inaugural class as a Distinguished Graduate of the United States Military A … gnized by the Horatio Alger Association by receiving its Distinguished American award. Pete is Senior Advisor to Virtu Financial, the world’s largest Electronic Market Making firm. Pete has one adult daughter, Noël, and six grandchildren. His wife of 55 years, Judi, and son, Sean, passed away in 2017 and 2007, respectively. Location Our Mission The Rumson St. Patrick’s Day Parade celebrates Irish heritage and provides charitable gifts to loca
Jesus Amo-Aparicio, PhD | Parkinson's Disease JavaScript is currently disabled. Please enable JavaScript for an optimal experience. Skip to main content Animations Search Email Sign Up Log In Donate Now Home Page Are you looking for: ${result.term} Donate Now Menu Close Clear My Profile My Parkinson’s Library Log In Main navigation Why We Exist Why We Exist Our Mission Our Promise Our Impact Our Agenda Michael's Story Current Partnerships Parkinson's Research The State of the Field Our Research Strategy Key Research Initiatives Parkinson’s Biomarkers Prizes Understanding Parkinson's Under … on's Library Educational Guides For Researchers For Researchers Funding What We Fund Funding Opportunities Funded Studies Open Science & Research Integrity Resources Research Tools Data Resources Biospecimens Patient Engagement Research News Podcasts MJFF Scientific Publications Collaboration Collaborative Research Opportunities Industry Partners Working with Us Key Initiatives and Findings PPMI Clinical Study ASAP Initiative GP2 Take Action Take Action Donate Donate Now Ways
Assessing the Ability of Dapansutrile, a Selective, Oral Inhibitor of the NLRP3 Neuroinflammatory Pathway, to Mitigate Progression of Parkinson’s Disease | Parkinson's Disease JavaScript is currently disabled. Please enable JavaScript for an optimal experience. Skip to main content Animations Search Email Sign Up Log In Donate Now Home Page Are you looking for: ${result.term} Donate Now Menu Close Clear My Profile My Parkinson’s Library Log In Main navigation Why We Exist Why We Exist Our Mission Our Promise Our Impact Our Agenda Michael's Story Current Partnerships Parkinson's Research T … on's Library Educational Guides For Researchers For Researchers Funding What We Fund Funding Opportunities Funded Studies Open Science & Research Integrity Resources Research Tools Data Resources Biospecimens Patient Engagement Research News Podcasts MJFF Scientific Publications Collaboration Collaborative Research Opportunities Industry Partners Working with Us Key Initiatives and Findings PPMI Clinical Study ASAP Initiative GP2 Take Action Take Action Donate Donate Now Ways
dapansutrile | Ligand page | IUPHAR/BPS Guide to MALARIA PHARMACOLOGY --> --> Home About About The Guide to MALARIA PHARMACOLOGY The Guide to PHARMACOLOGY About The Guide to PHARMACOLOGY About NC-IUPHAR Contributors Sponsors Citing Linking to us FAQ --> Disclaimer Privacy and Cookie Policy Targets Antimalarial targets Ligands Ligand list Ligand families Ligand search Lifecycle Plasmodium liver stage Plasmodium dormant liver stage Plasmodium asexual blood stage Plasmodium sexual blood stage Plasmodium mosquito host Pathways Pathway 1 Pathway 2 --> Species P. falciparum P. vivax P. knowlesi P. b … endorsement by NC-IUPHAR. Links are provided in return for sponsorship, used to fund improvements to this database. The sponsorship account is managed and audited by the University of Edinburgh, a charitable body registered in Scotland, SC005336. If you are interested in sponsoring the database, please contact us . ✖ Dapansutrile (links to external site) Cat. No. HY-17629 Contact us Privacy and Cookie Policy Sponsors list This work is licensed under a Creative Commons
Olatec Publications - Olatec An Emerging Paradigm Change in the Treatment of Multiple Diseases Home Leadership Management Scientific Advisory Board Clinical Advisory Board Board of Directors Products Lead Compound Science Olatec Publications Trials News & Events Contact Us Olatec's Publications ​ (click on title to link to publication ) Mechanism of Action ​ OLT1177, a β-sulfonyl nitrile compound, safe in humans, inhibits the NLRP3 inflammasome and reverses the metabolic cost of inflammation . Marchetti, C., Swartzwelter, B., Gamboni, F., Neff, C. P., Richter, K., Azam,
dapansutrile | Ligand page | IUPHAR/BPS Guide to PHARMACOLOGY --> --> Home About About The Guide to PHARMACOLOGY About NC-IUPHAR Database Content Contributors Sponsors Citing Linking to us FAQ --> Disclaimer Privacy and Cookie Policy Targets GPCRs Ion channels LGICs VGICs Other channels Nuclear receptors Kinases Catalytic receptors Transporters Enzymes Other protein targets Target search Target search tools BLAST Ligands Ligand list Ligand families Ligand search Diseases Resources Help Tutorial FAQ Terms and symbols Nomenclature guidelines Publications Antibacterials Drug approvals Downloads D … endorsement by NC-IUPHAR. Links are provided in return for sponsorship, used to fund improvements to this database. The sponsorship account is managed and audited by the University of Edinburgh, a charitable body registered in Scotland, SC005336. If you are interested in sponsoring the database, please contact us . ✖ Dapansutrile (links to external site) Cat. No. HY-17629 Contact us Privacy and Cookie Policy Sponsors list This work is licensed under a Creative Commons
Science - Olatec An Emerging Paradigm Change in the Treatment of Multiple Diseases Home Leadership Management Scientific Advisory Board Clinical Advisory Board Board of Directors Products Lead Compound Science Olatec Publications Trials News & Events Contact Us Dapansutrile is a leader in the development of the NLRP3 antagonist class therapeutics that target the body’s first line of immunological response in the innate immune system. Dapansutrile inhibits NLRP3, the sensor molecule integral in the formation of the NLRP3 inflammasome. Inflammasomes are multiprotein complexes in
DTXSID601336541 - BioCosm BioCosm Predictions Browse Estimates Every program, ranked by probability-of-success estimate Track Record How the estimates have held up against real outcomes Methodology The factors and base rates behind every estimate About MCP Contact Search ⌘K Map → DTXSID601336541 Olatec Therapeutics Executive Summary Dapansutrile is an oral NLRP3 inflammasome inhibitor from Olatec Therapeutics, now in a Cambridge-led Phase 2 trial (NCT07157735, the DAPA-PD study, n=36) testing whether dampening brain inflammation slows Parkinson's [1] [10] . The trial enrolls early-stage P … Phase 2 PD biomarker study transfers to Lilly [ 10 ] Michael J. Fox Foundation grant page and Frontiers Pharmacology 2025 review - DAPA-PD trial design, dose escalation, hsCRP enrollment criterion [ 11 ] Sánchez-Fernández et al, Frontiers in Immunology 2019 - OLT1177 oral BBB penetrance and efficacy in EAE; supplemented by intracerebral hemorrhage model (PMID 38492343) showing maintained BBB integrity and reduced microglial activation [ 12 ] Synapse patent landscape for dapa
Olatec Publications - Olatec An Emerging Paradigm Change in the Treatment of Multiple Diseases Home Leadership Management Scientific Advisory Board Clinical Advisory Board Board of Directors Products Lead Compound Science Olatec Publications Trials News & Events Contact Us Olatec's Publications ​ (click on title to link to publication ) Mechanism of Action ​ OLT1177, a β-sulfonyl nitrile compound, safe in humans, inhibits the NLRP3 inflammasome and reverses the metabolic cost of inflammation . Marchetti, C., Swartzwelter, B., Gamboni, F., Neff, C. P., Richter, K., Azam,
Dapansutrile - Drug Targets, Indications, Patents - Synapse Products Data Feature Plans Request Demo Sign Up for Free Last update 28 Feb 2026 Dapansutrile Last update 28 Feb 2026 Overview R&D Status Clinical Result Translational Medicine Deal Core Patent Clinical Trial Approval Regulation Overview Basic Info Drug Type Small molecule drug Synonyms Dapansutrile (USAN/INN), OLT 1177, OLT-1177 + [1] Target NLRP3 Action inhibitors Mechanism NLRP3 inhibitors(NACHT, LRR and PYD domains-containing protein 3 inhibitors) Therapeutic Areas Immune System Diseases Nervous System Diseases Congenital Dis … nificantly accelerate the time-to-market for PKM-01. PK MED is now entering the fund-raising phase to finance PKM-01 Phase II clinical trials. With robust patent protection and a clear path to deliver Phase II results, PKM-01 represents an attractive and low-risk opportunity for investors and partners.” Phase 2 Phase 3 Drug Approval IND 100 Deals associated with Dapansutrile Login to view more data External Link KEGG Wiki ATC Drug Bank D10920 Dapansutrile - DB16130 R&D St
Pipeline - Olatec An Emerging Paradigm Change in the Treatment of Multiple Diseases Home Leadership Management Scientific Advisory Board Clinical Advisory Board Board of Directors Products Lead Compound Science Olatec Publications Trials News & Events Contact Us Pipeline Products Products Lead Compound Olatec’s pharmaceutical platform is intended to address significant unmet needs in the treatment of inflammatory diseases. The Company’s Lead Compond, OLT1177TM dapansutrile is the only known selective NLRP3 inflammasome inhibitor in Phase 2 clinical trials in the US and E
Products - Olatec An Emerging Paradigm Change in the Treatment of Multiple Diseases Home Leadership Management Scientific Advisory Board Clinical Advisory Board Board of Directors Products Lead Compound Science Olatec Publications Trials News & Events Contact Us Our Products Products Lead Compound Olatec’s pharmaceutical platform is intended to address significant unmet needs in the treatment of acute and chronic inflammatory diseases. The Company’s lead compound, dapansutrile (lab code: OLT1177®) is a NLRP3 inhibitor in Phase 2 clinical trials in the US and Europe.& … ; If you are interested in OLT1177® for preclinical research, please submit a request through the contact form here . Home Leadership Management ​ Scientific Advisory Board ​Clinical Advisory Board Board of Directors Products Lead Compound Science Patients News & Events Contact Us Terms & Conditions | Privacy Policy | Sitemap OLATEC ® IS A REGISTERED TRADEMARK OF OLATEC THERAPEUTIC
Science - Olatec An Emerging Paradigm Change in the Treatment of Multiple Diseases Home Leadership Management Scientific Advisory Board Clinical Advisory Board Board of Directors Products Lead Compound Science Olatec Publications Trials News & Events Contact Us Dapansutrile is a leader in the development of the NLRP3 antagonist class therapeutics that target the body’s first line of immunological response in the innate immune system. Dapansutrile inhibits NLRP3, the sensor molecule integral in the formation of the NLRP3 inflammasome. Inflammasomes are multiprotein complexes in
Olatec - Home An Emerging Paradigm Change in the Treatment of Multiple Diseases Home Leadership Management Scientific Advisory Board Clinical Advisory Board Board of Directors Products Lead Compound Science Olatec Publications Trials News & Events Contact Us Olatec is dedicated to improving the health and physical well-being of patients around the world, through the development and commercialization of our platform of safe and effective pharmaceuticals that treat a broad spectrum of inflammatory diseases. ​Olatec is a privately held biopharmaceutical company developing a platform of safe
Olatec Presents Preclinical Evidence of Dapansutrile Activity in Parkinson's Menu Advanced Structure search List search Wish Lists Cart Sign in Sign in For suppliers --> Contact us Catalog of Screening Compounds Screening Libraries Building Blocks Al/ML Data sets new 1B virtual space new Advanced Structure search List search Homepage > Company > Media > Pharma News > 2026 > Olatec Presents Preclinical Evidence of Dapansutrile Activity in Parkinson's Olatec Presents Preclinical Evidence of Dapansutrile Activity in Parkinson's Olatec Presents Preclinical Evidence of Dapansutrile Activity in P
Access Denied Access Denied You don't have permission to access "http://www.businesswire.com/AK_PM_VPATH1/714432/bw_maintenance.html" on this server. Reference #18.11c41402.1782543533.1857565d https://errors.edgesuite.net/18.11c41402.1782543533.1857565d
Olatec Therapeutics, LLC | MTEC MTEC Focus Areas Who we serve Solicitations Patents About Us Explore Join MTEC Log In Life Sciences / Companies Olatec Therapeutics, LLC Olatec is a biopharmaceutical company dedicated to improving health through the development of safe and effective pharmaceuticals targeting inflammatory diseases. They focus on NLRP3 inflammasome inhibitors, with their lead compound dapansutrile (OLT1177®), which has shown clinical benefits in various inflammatory conditions. The company conducts operations in the US and Europe, with a team of experienced management and thought
Terms & Conditions - Olatec An Emerging Paradigm Change in the Treatment of Multiple Diseases Home Leadership Management Scientific Advisory Board Clinical Advisory Board Board of Directors Products Lead Compound Science Olatec Publications Trials News & Events Contact Us ​ Terms & Conditions Welcome to Olatec Therapeutics’ website. The contents of this website are owned and operated by Olatec Therapeutics LLC (“Olatec”). These Terms of Use (“Terms”) govern the use of this website. Please read the following information carefully before using th … laws of privacy and publicity, and/or other regulations and statutes. We grant you the right to view and use our Website subject to these Terms. You may download or print one copy of information provided in this Website for internal use only. Permission to reprint or electronically reproduce any document or graphic in whole or in part for any other purpose is expressly prohibited, unless prior written consent is obtained from us. Disclaimers THIS WEBSITE AND ITS CONTEN … n, nor do we adopt or endorse any such information. ​ Any information you submit ( e.g. , feedback, suggestions, ideas or comments) to Olatec via this Website--except for personally identifiable information which is covered by Olatec’s Privacy Policy -- is and will be treated as non-confidential and non-proprietary. Olatec shall be free to use, reproduce, disseminate, distribute and otherwise exploit such information without limitation, and without pro … NITED NATIONS CONVENTION ON THE INTERNATIONAL SALE OF GOODS. YOU AGREE TO SUBMIT TO THE EXCLUSIVE JURISDICTION OF THE STATE AND FEDERAL COURTS OF NEW YORK IN RELATION TO ANY CLAIM, DISPUTE OR DIFFERENCE ARISING FROM THESE TERMS, AND YOU AGREE TO WAIVE ANY RIGHT OF REMOVAL OR TRANSFER WHETHER DUE TO FORUM NON CONVENIENS OR OTHER REASON. These terms set forth the entire agreement between you and Olatec with respect to the subject matter hereof. Contact Us For further info
Olatec Therapeutics Presented Preclinical Evidence of Disease-Modifying Activity with Dapansutrile in its Parkinson's Studies Accessibility Statement Skip Navigation Resources Investor Relations Journalists Agencies Client Login Send a Release News Products Contact Search Search When typing in this field, a list of search results will appear and be automatically updated as you type. Searching for your content... No results found. Please change your search terms and try again. News in Focus Browse News Releases All News Releases All Public Company English-only News Releases Overview Multimedia … tform Login ProfNet Data Privacy Do not sell or share my personal information : Submit via [email protected] Call Privacy toll-free: 877-297-8921 Contact PR Newswire Products About My Services All News Releases Platform Login ProfNet Call PR Newswire at 888-776-0942 Terms of Use Privacy Policy Information Security Policy Site Map RSS Cookies Copyright © 2026 Cision US Inc. --> -->
Olatec Therapeutics LLC Company Profile: Financials, Valuation, and Growth | PrivCo Sign In Create Free Account PrivCo Olatec Therapeutics LLC Olatec Therapeutics LLC New York, NY Watchlist Export About Financials People Deals Funding About Olatec Therapeutics LLC Company overview Olatec Therapeutics LLC is a privately-held biopharmaceutical company that develops treatments for acute and chronic inflammatory diseases. Olatec Therapeutics LLC was founded in 2003 by Damaris Skouras. Olatec Therapeutics LLC headquarters are located in New York, New York. Keywords Revenue Revenue EBITDA EBITDA Val
Olatec Therapeutics Announces the Completion of First Dose Cohort in an Innovative Trial Investigating Olatec’s NLRP3 Inhibitor Dapansutrile and Merck’s Keytruda® - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug De … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Business Olatec Therapeutics Announces the Completion of First Dose Cohort in an Innovative Trial Investigating Olatec’s NLRP3 Inhibitor Dapansutrile and Merck’s Keytruda® May 16, 2023 | 11 min read Twitter LinkedIn Facebook Email Print Olatec Therapeutics Announces the Completion of First Dose Cohort … r scientist and assistant research professor at University of Colorado, secured grant funding to investigate the role of NLRP3 in Pancreatic Ductal Adenocarcinoma (PDAC). About Dapansutrile Dapansutrile (lab code: OLT1177 ® ) is an investigational small molecule, new chemical entity that specifically binds to and blocks NLRP3 (nucleotide-binding and oligomerization domain [NOD]‑, leucine rich repeat-, pyrin domain-containing 3), the sensor molecule integral in the formation o … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
WO2013130436A1 - Processus de préparation de 3-méthylsulfonylpropionitrile - Google Patents WO2013130436A1 - Processus de préparation de 3-méthylsulfonylpropionitrile - Google Patents Processus de préparation de 3-méthylsulfonylpropionitrile Download PDF Info Publication number WO2013130436A1 WO2013130436A1 PCT/US2013/027749 US2013027749W WO2013130436A1 WO 2013130436 A1 WO2013130436 A1 WO 2013130436A1 US 2013027749 W US2013027749 W US 2013027749W WO 2013130436 A1 WO2013130436 A1 WO 2013130436A1 Authority WO WIPO (PCT) Prior art keywords methylsulfonylpropionitrile ethanol organic solvent methy … is and makes no representation as to the accuracy of the status listed.) Ceased Application number PCT/US2013/027749 Other languages English ( en ) Inventor Joseph P. St. Laurent Gerald S. Jones David M. Bresse Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.) Olatec Therapeutics Inc Original Assignee Olatec Therapeutics Inc Priority date (The priority da … sted.) 2012-02-27 Filing date 2013-02-26 Publication date 2013-09-06 2013-02-26 Application filed by Olatec Therapeutics Inc filed Critical Olatec Therapeutics Inc 2013-02-26 Priority to KR1020147025857A priority Critical patent/KR102002664B1/ko 2013-02-26 Priority to CN201380011105.0A priority patent/CN104185621B/zh 2013-02-26 Priority to AU2013226300A priority patent/AU2013226300B2/en 2013-02-26 Priority to EP13755546.2A priority patent/EP2819995B1/fr 2013-02-26 Priority to … ing 3-methanesulfonylpropionitrile have been described in details in co-pending application 13/324,777, which is incorporated herein by reference in its entirety. FIG. 1A-1 C illustrate the process of Example 1. the methylhtiopropionitrile/acetic anhydride solution was slowly added to the reactor over 1 1 ⁇ 2-2 hr while maintaining a pot temperature of 30-34°C. the addition funnel was rinsed with 50 mL acetic anhydride and the reactor was then stirred for 10 minutes at 32 ⁇ 2 … hylsulfonylpropionitrile Ceased WO2013130436A1 ( fr ) Priority Applications (7) Application Number Priority Date Filing Date Title KR1020147025857A KR102002664B1 ( ko ) 2012-02-27 2013-02-26 3-메틸술포닐프로피오니트릴의 제조 방법 CN201380011105.0A CN104185621B ( zh ) 2012-02-27 2013-02-26 用于制备3-甲磺酰基丙腈的方法 AU2013226300A AU2013226300B2 ( en ) 2012-02-27 2013-02-26 P
Olatec Therapeutics’ Lead Compound, Dapansutrile, a Selective NLRP3 Inhibitor, Prevents the Inflammatory Response and Restores Cognitive and Behavioral Deficits in a Mouse Model of Alzheimer’s Disease - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE M … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Pharm Country Olatec Therapeutics’ Lead Compound, Dapansutrile, a Selective NLRP3 Inhibitor, Prevents the Inflammatory Response and Restores Cognitive and Behavioral Deficits in a Mouse Model of Alzheimer’s Disease December 29, 2020 | 6 min read Twitter LinkedIn Facebook Email Print The data are published in the Proceed … he public understanding of science, he was awarded with the Karl-Heinz-Beckurts prize and he was a founding member of the national Junge Akademie (Young Academy). About Dapansutrile Dapansutrile (lab code: OLT1177®) is an investigational small molecule, new chemical entity that specifically binds to and blocks NLRP3 (nucleotide-binding and oligomerization domain [NOD]-, leucine rich repeat-, pyrin domain-containing 3), the sensor molecule integral in the formation of the NLRP … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Olatec Presents Preclinical Evidence of Dapansutrile Activity in Parkinson's Menu Advanced Structure search List search Wish Lists Cart Sign in Sign in For suppliers --> Contact us Catalog of Screening Compounds Screening Libraries Building Blocks Al/ML Data sets new 1B virtual space new Advanced Structure search List search Homepage > Company > Media > Pharma News > 2026 > Olatec Presents Preclinical Evidence of Dapansutrile Activity in Parkinson's Olatec Presents Preclinical Evidence of Dapansutrile Activity in Parkinson's Olatec Presents Preclinical Evidence of Dapansutrile Activity in P
Privacy Policy - Olatec An Emerging Paradigm Change in the Treatment of Multiple Diseases Home Leadership Management Scientific Advisory Board Clinical Advisory Board Board of Directors Products Lead Compound Science Olatec Publications Trials News & Events Contact Us Privacy Policy The purpose of this policy is to provide you with information on how Olatec Therapeutics LLC (“Olatec” or “we”) will use and protect the personally identifiable information you share with us on this website (  www.olatec.com or Website ). This policy will be continuousl … rmation Olatec will collect personally identifiable information you voluntarily submit through our Website. This information includes but is not limited to: your name, e-mail address or organization. We will use your information only to respond to your requests. This Website is publicly available so you do not need to volunteer any personally identifiable information to us. Cookies Like many websites, this Website also uses a technology called “cookies”. A c … s reasonably necessary to (a) comply with law and legal process, (b) enforce or apply the terms of any of our user agreements, (c) protect the rights, property or safety of Olatec Therapeutics LLC, our users, or others; or (d) in relation to the sale, assignment, transfer or acquisition of all or substantially all of Olatec’s assets or shares by a third party. Protection of Children's Information Olatec’s dedication to protecting your privacy also … offer useful information. The policies and procedures we described here do not apply to those sites. We suggest contacting those sites directly for information on their privacy, security, and data collection and distribution policies. Tracking Olatec will not respond to web browser “do not track” signals. If you would like additional information about online tracking and various opt-out mechanisms, please see http://donottrack.us/ Because we link to social media
Olatec Therapeutics Announces the Completion of First Dose Cohort in an Innovative Trial Investigating Olatec’s NLRP3 Inhibitor Dapansutrile and Merck’s Keytruda in Patients with Advanced Refractory Melanoma at Duke Cancer Institute | FirstWord PHARMA You need to enable JavaScript to run this app. Loading...
Olatec Announces High-Impact Coverage of Dapansutrile in Leading Journal on Cardiovascular Disease as well as Another Publication from New Preclinical Data in a Heart Failure Model | FirstWord PHARMA You need to enable JavaScript to run this app. Loading...
News & Events - Olatec An Emerging Paradigm Change in the Treatment of Multiple Diseases Home Leadership Management Scientific Advisory Board Clinical Advisory Board Board of Directors Products Lead Compound Science Olatec Publications Trials News & Events Contact Us Recent News & Events Mar 24 First Parkinson’s Patients Treated in Landmark Phase 2 Trial of Dapansutrile – Expanding a Leading Oral NLRP3 Inhibitor into Neurological Disease New York, NY – March 24, 2026 – Olatec Therapeutics, Inc. (“Olatec”) developing one of the … ase with its NLRP3 Inhibitor, Dapansutrile Cure Parkinson’s has awarded a grant under its International Linked Clinical Trials (iLCT) program to support a clinical study of dapansutrile in patients with early Parkinson’s disease Caroline H. Williams-Gray BMBCh MRCP PhD will serve as Principal Investigator of this Phase 2 trial at the University of Cambridge in the UK, where Dr. Williams-Gray leads the Parkinson’s Disease Research Clinic. The trial will be su … ective NLRP3 inhibitors, today announced that Cure Parkinson’s granted an award to initiate a Phase 2 clinical trial investigating the potential of oral dapansutrile to slow or stop the progression of Parkinson’s disease... ​ (click on bold, green text for links ) Dec 10 During a 2023 American Society of Hematology Meeting last week, Dr. Isak Tengesdal presented a poster co-authored with Dr. Charles Dinarello " Metabolic Alterations Assoc … ma. ​Link to Full Press Release here Mar 10 Olatec Therapeutics Awarded a Grant from The Michael J. Fox Foundation in Collaboration With Medical University of Innsbruck to Evaluate Dapansutrile in Animal Models of Parkinson’s Disease Progression The Michael J. Fox Foundation for Parkinson’s Research (MJFF) has awarded a grant from their Therapeutics Pipeline Program to support preclinical research evaluating Olatec Therapeutics’ lead compound, dapansut … squo; lead compound, dapansutrile, in Parkinson’s disease (PD) Under this grant Olatec, in collaboration with Dr. Nadia Stefanova (Medical University of Innsbruck), will be studying dapansutrile in both wildtype and transgenic mice with α-synuclein inclusion pathology to assess dapansutrile’s effect on motor symptoms and lowerin
Access Denied Access Denied You don't have permission to access "http://www.businesswire.com/AK_PM_VPATH1/714432/bw_maintenance.html" on this server. Reference #18.d0a0d517.1782540889.6ba37354 https://errors.edgesuite.net/18.d0a0d517.1782540889.6ba37354
Olatec Therapeutics Enrolls its First Patients in a Phase 2 Clinical Trial in COVID-19 with its Selective NLRP3 Inhibitor, Oral Dapansutrile | FirstWord PHARMA You need to enable JavaScript to run this app. Loading...
Olatec initiates dapansutrile Phase II diabetes trial Skip to site menu Skip to page content Switch language: .translate --> CT Menu Search Sections Home News Analysis Features Comment & Opinion Projects Data Insights Sectors Clinical Trials Approvals Operations Outsourced Services Supply Chain Data Management Medical Devices Themes Artificial Intelligence Cloud Corporate Governance Cybersecurity Environmental Sustainability Internet of Things Robotics Social Responsibility Covid-19 Insights Deals Jobs Filings Patents Social Media Companies Company A-Z Company Categories Product & Services Com … Chain Data Management Medical Devices Latest Ollin Biosciences secures $330m to fund Phase III OLN324 trials Viking Therapeutics commences Phase I trial of VK3019 Ascletis receives FDA clearance for Phase I trial of obesity treatment Themes Sections Artificial Intelligence Cloud Corporate Governance Cybersecurity Environmental Sustainability Internet of Things Robotics Social Responsibility Covid-19 Foreign Direct Investment Latest How wearables can unlock their full potentia … nflammation due to NLRP3/IL-1 activation.” Earlier this year, Olatec received a grant to commence a Phase II clinical trial of dapansutrile to slow down or stop Parkinson’s disease progression. --> Sign up for our daily news round-up! Give your business an edge with our leading industry insights. Sign up Share Copy Link Share on X Share on Linkedin Share on Facebook Go deeper with GlobalData Reports LOA and PTSR Model - Dapansutrile in Melanoma Reports LOA and PTSR Model - Oz
Alberto Mantovani, MD Joins Olatec Therapeutics’ Scientific Advisory Board - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opini … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Business Alberto Mantovani, MD Joins Olatec Therapeutics’ Scientific Advisory Board July 8, 2021 | 5 min read Twitter LinkedIn Facebook Email Print Olatec Therapeutics LLC is very pleased to welcome Alberto Mantovani MD to its Scientific Advisory Board. NEW YORK--( BUSINESS WIRE )-- Olatec Therapeutic … i received several Italian and international awards, such as the Triennial OECI Award from the Organization of the European Cancer Institutes, the Robert Koch Award for his contribution to tumor immunology and immunotherapy, the American-Italian Cancer Foundation (AICF) Prize for Excellence in Medicine and the American Association for Cancer Research International Pezcoller Award for Extraordinary Achievement in Cancer Research. The broad impact of Dr. Mantovani’s contributio … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Access Denied Access Denied You don't have permission to access "http://www.businesswire.com/AK_PM_VPATH1/714432/bw_maintenance.html" on this server. Reference #18.d0a0d517.1782543651.6bfd1ec6 https://errors.edgesuite.net/18.d0a0d517.1782543651.6bfd1ec6
VentureRadar 0){if($('#i_b_toggleMore').hasClass('active')){Search_Elastic();}else{Search_DeconstructSearchString();Search_Elastic(false);event.preventDefault();}}else{event.preventDefault();}}" onclick="this.removeAttribute('readonly');" ontouchstart="this.removeAttribute('readonly');" id="i_t_Search" name="VRSearch" readonly> All Ranked Organisation Names Apps and Links Homepage (myVR) Funding Deals Hub Similar Companies App Articles Manage Account Logout Login Free Sign-up Forgotten your password? By continuing, you agree to VentureRadar's Terms of Service , Privacy Policy and Cookie … de Therapies; Vaccines; Biotech Show more Show less Updates All Funding Insight Grant Award Conference Competition Research Website Traffic Trend Business InsighT 01 Dec 2020 Website traffic has increased in the past 3 months, up from a ranking of 676,733 to 376,314. Source: Data from alexa.com COVID-19 vaccine tracker - London School of Hygiene & Tropical Medicine Research Report 20 Sep 2020 [BioNTech; Fosun Pharma; Pfizer] listed among those developing/researching a COVID-1 … ene therapy to cost $850,000 per patient | Reuters Source: reuters.com The STEP Award (2011) Award 29 Nov 2011 Category Winner: Finances Source: The STEP Award (2011) Show less Funding Signals VENTURE FUNDED Venture-funding News Venture-funding News Venture-funding News Related Top Ranked Companies Lists Life Sciences Biologics Healthtech Sars-Cov-2 Vaccine Cancer Melanoma Immunotherapy Diagnostics Dna Rna Peptide Therapies Vaccines Biotech Website Archive 2022 2023 2024 2025 … search results. Please select a Type Funding Round Team Products & Technologies Grant Award Conference Competition Other {DETAIL_VALUE} Remove Upgrade for full access You have reached your free usage limit for today. Upgrade to a paid plan for: Unlimited search alerts 250 records per export Unlimited pages and searches Full Access from $ 60.00 per month Upgrade Now Your VentureRadar Business account is now active and your account information has been sent to … nditions Privacy Policy Cookie Policy Contact Us Twitter LinkedIn | Submit a Company Directory of Companies Login Free Sign-up for VentureRadar access or By continuing, you agree to VentureRadar's Terms of Service , Privacy Policy and Cookie Policy . Free Sign-up for VentureRadar access You must have cookies enabled to create an accou
Olatec Therapeutics | Olatec Therapeutics LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement , Privacy Policy , and Cookie
Olatec | Biotech Careers Skip to main content Biotech Careers Contact Submit an Employer Contact Add an Employer Search Open main menu Contact Submit an Employer Contact Add an Employer Search Main navigation Careers Job Areas People Articles Videos Biotech Companies Biotech Jobs Business Areas Olatec Website: Olatec Business Area(s) Small Molecules Inflammation Description Olatec is a privately held biopharmaceutical company developing a platform of safe, oral NLRP3 antagonist therapeutics, to treat and prevent a broad spectrum of acute and chronic inflammatory diseases that are known to be m
Andy Cunningham Joins Olatec Therapeutics Board of Directors Accessibility Statement Skip Navigation Resources Investor Relations Journalists Agencies Client Login Send a Release News Products Contact Search Search When typing in this field, a list of search results will appear and be automatically updated as you type. Searching for your content... No results found. Please change your search terms and try again. News in Focus Browse News Releases All News Releases All Public Company English-only News Releases Overview Multimedia Gallery All Multimedia All Photos All Videos Multimedia Gallery O … tform Login ProfNet Data Privacy Do not sell or share my personal information : Submit via [email protected] Call Privacy toll-free: 877-297-8921 Contact PR Newswire Products About My Services All News Releases Platform Login ProfNet Call PR Newswire at 888-776-0942 Terms of Use Privacy Policy Information Security Policy Site Map RSS Cookies Copyright © 2026 Cision US Inc. --> -->
Olatec - Home An Emerging Paradigm Change in the Treatment of Multiple Diseases Home Leadership Management Scientific Advisory Board Clinical Advisory Board Board of Directors Products Lead Compound Science Olatec Publications Trials News & Events Contact Us Olatec is dedicated to improving the health and physical well-being of patients around the world, through the development and commercialization of our platform of safe and effective pharmaceuticals that treat a broad spectrum of inflammatory diseases. ​Olatec is a privately held biopharmaceutical company developing a platform of safe
Olatec Therapeutics Awarded a Grant from The Michael J. Fox Foundation in Collaboration With Medical University of Innsbruck to Evaluate Dapansutrile in Animal Models of Parkinson’s Disease Progression - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Pharm Country Olatec Therapeutics Awarded a Grant from The Michael J. Fox Foundation in Collaboration With Medical University of Innsbruck to Evaluate Dapansutrile in Animal Models of Parkinson’s Disease Progression March 10, 2023 | 9 min read Twitter LinkedIn Facebook Email Print Olatec Therapeutics LLC (Olatec), a lea … he Michael J. Fox Foundation for Parkinson’s Research (MJFF) awarded a research grant to evaluate Olatec’s lead molecule, dapansutrile, in preclinical Parkinson’s disease (PD) progression models. The Michael J. Fox Foundation for Parkinson’s Research (MJFF) has awarded a grant from their Therapeutics Pipeline Program to support preclinical research evaluating Olatec Therapeutics’ lead compound, dapansutrile, in Parkinson’s disease (PD) Under this grant Olatec, in colla … hael J. Fox Foundation for Parkinson’s Research (MJFF) awarded a research grant to evaluate Olatec’s lead molecule, dapansutrile, in preclinical Parkinson’s disease (PD) progression models. These studies are being initiated in collaboration with researchers at the Medical University of Innsbruck in Austria. The studies will assess dapansutrile’s potential effect as an anti-neuroinflammatory agent, and its pharmacokinetics to confirm validated target engagement in certai … prevent or slow formation of α‑synuclein aggregation. When asked about the MJFF grant, Charles Dinarello MD, Olatec SAB Chair, said: “The data we have generated using a standard mouse model of Parkinson's disease allow us to advance our findings with the models to be used by Dr. Stefanova. Specifically, our current data reveal that dapansutrile’s
Olatec Therapeutics LLC Announces a Scientific Publication on the Positive Results in the First Known Clinical Trial with a Selective Oral NLRP3 Inhibitor, Dapansutrile, in Patients with Heart Failure - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE M … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Drug Development Olatec Therapeutics LLC Announces a Scientific Publication on the Positive Results in the First Known Clinical Trial with a Selective Oral NLRP3 Inhibitor, Dapansutrile, in Patients with Heart Failure February 11, 2021 | 7 min read Twitter LinkedIn Facebook Email Print Olatec Therapeu … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Olatec Therapeutics Announces the Final Closing, Led by Sanders Morris Harris, on Its $40 Million Series A Financing Round - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Busine … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Pharm Country Olatec Therapeutics Announces the Final Closing, Led by Sanders Morris Harris, on Its $40 Million Series A Financing Round February 23, 2023 | 7 min read Twitter LinkedIn Facebook Email Print Olatec Therapeutics LLC (“ Olatec ” or the “ Company ”), a leader in developing NLRP3 inhibitors, announced the com … a bachelor’s degree in pharmacy from Texas Southern University. He completed a fellowship in primary care policy with the U.S. Department of Health & Human Services and residencies in occupational and family medicine at the University of Texas Health Science Center and aviation medicine instruction at the U.S. Army School of Aerospace Medicine. About Olatec Therapeutics LLC Olatec is a privately held, Phase 2/3 clinical-stage biopharmaceutical company developing a platfo … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Products - Olatec An Emerging Paradigm Change in the Treatment of Multiple Diseases Home Leadership Management Scientific Advisory Board Clinical Advisory Board Board of Directors Products Lead Compound Science Olatec Publications Trials News & Events Contact Us Our Products Products Lead Compound Olatec’s pharmaceutical platform is intended to address significant unmet needs in the treatment of acute and chronic inflammatory diseases. The Company’s lead compound, dapansutrile (lab code: OLT1177®) is a NLRP3 inhibitor in Phase 2 clinical trials in the US and Europe.& … ; If you are interested in OLT1177® for preclinical research, please submit a request through the contact form here . Home Leadership Management ​ Scientific Advisory Board ​Clinical Advisory Board Board of Directors Products Lead Compound Science Patients News & Events Contact Us Terms & Conditions | Privacy Policy | Sitemap OLATEC ® IS A REGISTERED TRADEMARK OF OLATEC THERAPEUTIC
Pipeline - Olatec An Emerging Paradigm Change in the Treatment of Multiple Diseases Home Leadership Management Scientific Advisory Board Clinical Advisory Board Board of Directors Products Lead Compound Science Olatec Publications Trials News & Events Contact Us Pipeline Products Products Lead Compound Olatec’s pharmaceutical platform is intended to address significant unmet needs in the treatment of inflammatory diseases. The Company’s Lead Compond, OLT1177TM dapansutrile is the only known selective NLRP3 inflammasome inhibitor in Phase 2 clinical trials in the US and E
WO2013130436A1 - Process for preparing 3-methylsulfonylpropionitrile - Google Patents WO2013130436A1 - Process for preparing 3-methylsulfonylpropionitrile - Google Patents Process for preparing 3-methylsulfonylpropionitrile Download PDF Info Publication number WO2013130436A1 WO2013130436A1 PCT/US2013/027749 US2013027749W WO2013130436A1 WO 2013130436 A1 WO2013130436 A1 WO 2013130436A1 US 2013027749 W US2013027749 W US 2013027749W WO 2013130436 A1 WO2013130436 A1 WO 2013130436A1 Authority WO WIPO (PCT) Prior art keywords methylsulfonylpropionitrile ethanol organic solvent methylthiopropionitrile … is and makes no representation as to the accuracy of the status listed.) Ceased Application number PCT/US2013/027749 Other languages English ( en ) French ( fr ) Inventor Joseph P. St. Laurent Gerald S. Jones David M. Bresse Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.) Olatec Therapeutics Inc Original Assignee Olatec Therapeutics Inc Priority date (T … sted.) 2012-02-27 Filing date 2013-02-26 Publication date 2013-09-06 2013-02-26 Application filed by Olatec Therapeutics Inc filed Critical Olatec Therapeutics Inc 2013-02-26 Priority to KR1020147025857A priority Critical patent/KR102002664B1/ko 2013-02-26 Priority to CN201380011105.0A priority patent/CN104185621B/zh 2013-02-26 Priority to AU2013226300A priority patent/AU2013226300B2/en 2013-02-26 Priority to EP13755546.2A priority patent/EP2819995B1/en 2013-02-26 Priority to … ing 3-methanesulfonylpropionitrile have been described in details in co-pending application 13/324,777, which is incorporated herein by reference in its entirety. FIG. 1A-1 C illustrate the process of Example 1. the methylhtiopropionitrile/acetic anhydride solution was slowly added to the reactor over 1 1 ⁇ 2-2 hr while maintaining a pot temperature of 30-34°C. the addition funnel was rinsed with 50 mL acetic anhydride and the reactor was then stirred for 10 minutes at 32 ⁇ 2 … hylsulfonylpropionitrile Ceased WO2013130436A1 ( en ) Priority Applications (7) Application Number Priority Date Filing Date Title KR1020147025857A KR102002664B1 ( ko ) 2012-02-27 2013-02-26 3-메틸술포닐프로피오니트릴의 제조 방법 CN201380011105.0A CN104185621B ( zh ) 2012-02-27 2013-02-26 用于制备3-甲磺酰基丙腈的方法 AU2013226300A AU2013226300B2 ( en ) 2012-02-27 2013-02-26 P
Olatec Therapeutics LLC - Drug pipelines, Patents, Clinical trials - Synapse Products Data Feature Plans Request Demo Sign Up for Free Last update 04 Mar 2026 Olatec Therapeutics LLC Holding Company | 2003 | New York, United States | < 10 | www.olatec.com Holding Company | 2003 | New York, United States | < 10 | www.olatec.com Last update 04 Mar 2026 Overview Pipeline Deal Translational Medicine Profit Grant & Funding(NIH) Investment Financing Overview Tags Endocrinology and Metabolic Disease Skin and Musculoskeletal Diseases Other Diseases Small molecule drug Disease domain score A … million purchase of Ventyx stock in 2024. Four days later, Lilly made its first proposal at $12.50 per share in cash. Ventyx’s board wanted more and considered the initial proposal “insufficient.” Such reply is relatively standard in biopharma M&A deal discussions. It was coming up on the holidays, and Ventyx wanted to know whether Sanofi and Party A would also make an offer. Both companies replied that they wouldn’t accelerate their due diligence processes during the winter … ec. 30. The clock struck 2026, and a day later, Lilly sent its “best and final” proposal of $14 per share. On Jan. 7, they sealed the deal and announced it to the market. Lilly would get a small biotech with a pipeline spanning autoimmune, cardiovascular and neurological conditions. The Lilly-Ventyx deal marked the second biotech acquisition of the year. Industry insiders had expected more dealmaking heading into the JP Morgan Healthcare Conference, but none materialized. A w … h the help of its Chemistry42 platform. Hygtia was incubated by Shenzhen Pengfu Fund, which is backed by Fosun Health Capital and Fosun Pharma. The biotech was founded in August last year with a focus on advancing treatments for autoimmune diseases and “related areas.” Phase 2 Phase 1 Acquisition License out/in 100 Deals associated with Olatec Therapeutics LLC Login to view more data 100 Translational Medicine associated with Olatec Therapeutics LLC Login to view more data Co … itions of over 360K organizations with Synapse. login or view full example data Grant & Funding(NIH) Access more than 2 million grant and funding information to elevate your research journey. login or view full example data Investment Gain insights on the latest company investments from start-ups to established corporations. login or view ful
Charles A. Dinarello - Chairman, SAB & co-Chief Scientific Officer at Olatec Therapeutics | The Org Platform Enrich Pricing Log in Sign up Olatec Therapeutics Charles A. Dinarello Unverified CD Charles A. Dinarello Chairman, SAB & co-Chief Scientific Officer Contact Charles A. Dinarello, MD serves as Chairman of Olatec's Scientific Advisory Board and Chief Scientific Officer. Dr. Dinarello joined Olatec’s Drug Development Team in January 2014 and became a member of the Scientific Advisory Board in May 2014. Dr. Dinarello elucidated the mechanism of action of dapansutrile (OLT117 … is contributions to the field of cytokines and medicine, he received the Squibb Award (USA), Ernst Jung Prize in Medicine (Germany), Gold Medal of the Heilmeyer Society for Internal Medicine (Germany), Chirone Prize (Italian National Academy of Medicine), Carol Nachman Prize (Germany), Sheikh Hamdan bin Rashdid al Maktoum Award (United Arab Emirates), Beering Prize (USA), Albany Prize in Medical Research (USA), Crafoord Prize of the Royal Swedish Academy of Sciences (Sweden), … Crafoord Prize of the Royal Swedish Academy of Sciences (Sweden), Paul Ehrlich Prize (Germany), Bonfils-Stanton Prize (USA), the Novartis Prize in Clinical Immunology (Switzerland), the Bonazinga Award (USA) and Drexel Prize in Immunology (USA). Dr. Dinarello received the Lifetime Achievement Award of the Eicosanoid Foundation for his pioneering studies on the role of lipids in cytokine-mediated inflammation. In 2017, Dr. Dinarello was awarded the Meinhard von Pflaundler Med … ard von Pflaundler Medal, Ludwig Maximillan University (Germany) and the Cerami Prize (USA). In 2020, Dr. Dinarello received the Tang Prize (Taiwan). Dr. Dinarello donates the monies from his awards and prizes to The Interleukin Foundation, a charitable foundation he established in 2009, which supports research on cytokines, particularly to young investigators. Org chart View org chart 1 View manager View position No direct reports Teams View all teams Clinical Development 2
Leadership - Olatec An Emerging Paradigm Change in the Treatment of Multiple Diseases Home Leadership Management Scientific Advisory Board Clinical Advisory Board Board of Directors Products Lead Compound Science Olatec Publications Trials News & Events Contact Us Management Management Scientific Advisory Board Clinical Advisory Board Board of Directors ​ Damaris B. Skouras | Founder, Chairman, Chief Executive Officer Ms. Skouras, a co-founder of Olatec, served as President until 2013 when she became Chairman and CEO. Ms. Skouras has over 20 years of experience in pharmaceutic … is contributions to the field of cytokines and medicine, he received the Squibb Award (USA), Ernst Jung Prize in Medicine (Germany), Gold Medal of the Heilmeyer Society for Internal Medicine (Germany), Chirone Prize (Italian National Academy of Medicine), Carol Nachman Prize (Germany), Sheikh Hamdan bin Rashdid al Maktoum Award (United Arab Emirates), Beering Prize (USA), Albany Prize in Medical Research (USA), Crafoord Prize of the Royal Swedish Academy of Sciences (Sweden), … Crafoord Prize of the Royal Swedish Academy of Sciences (Sweden), Paul Ehrlich Prize (Germany), Bonfils-Stanton Prize (USA), the Novartis Prize in Clinical Immunology (Switzerland), the Bonazinga Award (USA) and Drexel Prize in Immunology (USA). Dr. Dinarello received the Lifetime Achievement Award of the Eicosanoid Foundation for his pioneering studies on the role of lipids in cytokine-mediated inflammation. In 2017, Dr. Dinarello was awarded the Meinhard von Pflaundl … ard von Pflaundler Medal, Ludwig Maximillan University (Germany) and the Cerami Prize (USA). Dr. Dinarello donates the monies from his awards and prizes to The Interleukin Foundation, a charitable foundation he established in 2009, which supports research on cytokines, particularly to young investigators. ​ Joseph St. Laurent | co-Chief Scientific Officer Joseph P. St. Laurent serves as the Olatec’s co-Chief Scientific Officer. Since July 2005, Mr
Management - Olatec An Emerging Paradigm Change in the Treatment of Multiple Diseases Home Leadership Management Scientific Advisory Board Clinical Advisory Board Board of Directors Products Lead Compound Science Olatec Publications Trials News & Events Contact Us Management Management Scientific Advisory Board Clinical Advisory Board Board of Directors ​ Damaris B. Skouras | Founder, Chairman, Chief Executive Officer Ms. Skouras, a co-founder of Olatec, served as President until 2013 when she became Chairman and CEO. Under her leadership, Ms. Skouras and the team she built have de … is contributions to the field of cytokines and medicine, he received the Squibb Award (USA), Ernst Jung Prize in Medicine (Germany), Gold Medal of the Heilmeyer Society for Internal Medicine (Germany), Chirone Prize (Italian National Academy of Medicine), Carol Nachman Prize (Germany), Sheikh Hamdan bin Rashdid al Maktoum Award (United Arab Emirates), Beering Prize (USA), Albany Prize in Medical Research (USA), Crafoord Prize of the Royal Swedish Academy of Sciences (Sweden), … Crafoord Prize of the Royal Swedish Academy of Sciences (Sweden), Paul Ehrlich Prize (Germany), Bonfils-Stanton Prize (USA), the Novartis Prize in Clinical Immunology (Switzerland), the Bonazinga Award (USA) and Drexel Prize in Immunology (USA). Dr. Dinarello received the Lifetime Achievement Award of the Eicosanoid Foundation for his pioneering studies on the role of lipids in cytokine-mediated inflammation. In 2017, Dr. Dinarello was awarded the Meinh … ard von Pflaundler Medal, Ludwig Maximillan University (Germany) and the Cerami Prize (USA). In 2020, Dr. Dinarello received the Tang Prize (Taiwan). Dr. Dinarello donates the monies from his awards and prizes to The Interleukin Foundation, a charitable foundation he established in 2009, which supports research on cytokines, particularly to young investigators. ​ Joseph St. Laurent | co-Chief Scientific Officer Joseph P. St. Laurent se
Scientific Advisory Board - Olatec An Emerging Paradigm Change in the Treatment of Multiple Diseases Home Leadership Management Scientific Advisory Board Clinical Advisory Board Board of Directors Products Lead Compound Science Olatec Publications Trials News & Events Contact Us Scientific Advisory Board Management Scientific Advisory Board Clinical Advisory Board Board of Directors Charles A. Dinarello, MD | SAB Chairman, co-Chief Scientific Officer Charles A. Dinarello, MD serves as Chairman of Olatec's Scientific Advisory Board and Chief Scientific Officer. Dr. Dinar … is contributions to the field of cytokines and medicine, he received the Squibb Award (USA), Ernst Jung Prize in Medicine (Germany), Gold Medal of the Heilmeyer Society for Internal Medicine (Germany), Chirone Prize (Italian National Academy of Medicine), Carol Nachman Prize (Germany), Sheikh Hamdan bin Rashdid al Maktoum Award (United Arab Emirates), Beering Prize (USA), Albany Prize in Medical Research (USA), Crafoord Prize of the Royal Swedish Academy of Sciences (Sweden), … Crafoord Prize of the Royal Swedish Academy of Sciences (Sweden), Paul Ehrlich Prize (Germany), Bonfils-Stanton Prize (USA), the Novartis Prize in Clinical Immunology (Switzerland), the Bonazinga Award (USA) and Drexel Prize in Immunology (USA). Dr. Dinarello received the Lifetime Achievement Award of the Eicosanoid Foundation for his pioneering studies on the role of lipids in cytokine-mediated inflammation. In 2017, Dr. Dinarello was awarded the Meinh … ard von Pflaundler Medal, Ludwig Maximillan University (Germany) and the Cerami Prize (USA). Dr. Dinarello donates the monies from his awards and prizes to The Interleukin Foundation, a charitable foundation he established in 2009, which supports research on cytokines, particularly to young investigators. ​ Carlo Marchetti, PhD | Director for Olatec’s Innovative Science Program in Dinarello’s Laboratory ​ In June 2015, Carlo M … egree from University Campus Bio-Medico of Rome, Italy and completed a Clinical Fellowship in Adult Cardiovascular Medicine and a PhD in Molecular and Cellular Cardiology at the Catholic University of the Sacred Heart, Rome, Italy. In Rome, Dr. Abbate trained under Drs. Attilio Maseri and Filippo Crea. Dr. Maseri’s group pioneere
Olatec Therapeutics Presented Preclinical Evidence of Disease-Modifying Activity with Dapansutrile in its Parkinson's Studies - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deal … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases Olatec Therapeutics Presented Preclinical Evidence of Disease-Modifying Activity with Dapansutrile in its Parkinson’s Studies January 21, 2026 | 5 min read Twitter LinkedIn Facebook Email Print NEW YORK , Jan. 20, 2026 /PRNewswire/ -- Olatec Therapeutics, Inc. ("Olatec"), a clinical stage biotechnol … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Board of Directors - Olatec An Emerging Paradigm Change in the Treatment of Multiple Diseases Home Leadership Management Scientific Advisory Board Clinical Advisory Board Board of Directors Products Lead Compound Science Olatec Publications Trials News & Events Contact Us Board of Directors Management Scientific Advisory Board Clinical Advisory Board Board of Directors Damaris B. Skouras | Founder, Chairman, Chief Executive Officer Ms. Skouras, a co-founder of Olatec, served as President until 2013 when she became Chairman and CEO. Ms. Skouras has over 30 years of drug development e
Parkinson’s preclinical research on dapansutrile awarded grant | Funding to go toward potential therapy to prevent, lessen Parkinson's symptoms | Parkinson's News Today Skip to content Newsletter Search Search for: Search Toggle navigation Search for: Search About Parkinson's Toggle menu: About Parkinson's What is Parkinson’s disease? Causes Diagnosis Symptoms Motor symptoms Nonmotor symptoms Types Treatments Approved treatments Experimental treatments Non-drug treatments Living with Toggle menu: Living with Exercise Diet Parkinson’s progression News Community Toggle menu: Community … Advocacy partners News Parkinson’s preclinical research on dapansutrile awarded grant Parkinson’s preclinical research on dapansutrile awarded grant Funding to go toward potential therapy to prevent, lessen Parkinson's symptoms Written by Patricia Valerio, PhD | March 13, 2023 Discuss Share Share this page with email Share this page on Facebook Share this page on X Share this page on Reddit Print Preferred Source on Google Olatec Therapeutics has been awa … Print Preferred Source on Google Olatec Therapeutics has been awarded a grant from the Michael J. Fox Foundation for Parkinson’s Research (MJFF) to further investigate its lead oral candidate, dapansutrile, in animal models of Parkinson’s disease . Such preclinical work will be conducted in collaboration with researchers at the Medical University of Innsbruck in Austria to accelerate the development of this potential therapy to prevent or lessen the development of the … apy to prevent or lessen the development of the disease’s symptoms . Under this grant, of which the amount was not specified, the team will evaluate dapansutrile’s potential as an anti-neuroinflammatory therapy in specific Parkinson’s mouse models. “We are very pleased to receive this grant from the MJFF and are hopeful the findings will advance us into a clinical trial with dapansutrile in Parkinson’s disease,” Charles Dinarello, MD, Olatec ’s scientific advisory board chair … scription of their awarded project . “Olatec is very pleased to be awarded this grant, and to be collaborating with Dr. Stefanova on this important research evaluating dapansutrile in the potential treatment of this debilitating disease with unmet medical need,” said Damaris Skouras, Olatec’s founder and CEO. Discuss Share Share this page
US11857529B2 - Methods for treating melanoma - Google Patents US11857529B2 - Methods for treating melanoma - Google Patents Methods for treating melanoma Download PDF Info Publication number US11857529B2 US11857529B2 US17/021,733 US202017021733A US11857529B2 US 11857529 B2 US11857529 B2 US 11857529B2 US 202017021733 A US202017021733 A US 202017021733A US 11857529 B2 US11857529 B2 US 11857529B2 Authority US United States Prior art keywords melanoma tumor dapansutrile cells diet Prior art date 2018-03-21 Legal status (The legal status is an assumption and is not a legal conclusion. Google has no … sentation as to the accuracy of the status listed.) Active , expires 2041-01-14 Application number US17/021,733 Other versions US20200405681A1 ( en Inventor Carlo MARCHETTI Charles A. Dinarello Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.) Olatec Therapeutics Inc Original Assignee Olatec Therapeutics Inc Priority date (The priority date is an assumpti … sted.) 2018-03-21 Filing date 2020-09-15 Publication date 2024-01-02 2020-09-15 Application filed by Olatec Therapeutics Inc filed Critical Olatec Therapeutics Inc 2020-09-15 Priority to US17/021,733 priority Critical patent/US11857529B2/en 2020-09-15 Assigned to OLATEC THERAPEUTICS LLC reassignment OLATEC THERAPEUTICS LLC ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: DINARELLO, CHARLES A., MARCHETTI, Carlo 2020-12-31 Publication of US20200405681A1 p … NAME (SEE DOCUMENT FOR DETAILS). Assignors: OLATEC THERAPEUTICS LLC 2024-01-02 Application granted granted Critical 2024-01-02 Publication of US11857529B2 publication Critical patent/US11857529B2/en Status Active legal-status Critical Current 2041-01-14 Adjusted expiration legal-status Critical Links USPTO USPTO PatentCenter USPTO Assignment Espacenet Global Dossier Discuss Images Classifications A — HUMAN NECESSITIES A61 — MEDICAL OR VETERINARY SCIENCE; HYGIENE … l physical form A61K9/0012 — Galenical forms characterised by the site of application A61K9/0053 — Mouth and digestive tract, i.e. intraoral and peroral administration Definitions the present invention relates to methods for treating melanoma by administering an effective amount of dapansutrile. Tumorigenesis is initiated by genomic a